ALNYLAM PHARMACEUTICALS, INC. Fair Value, Equity, Level 2 to Level 1 Transfers, Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Fair Value, Equity, Level 2 to Level 1 Transfers, Amount of $0 as of 2014-03-31, per its 10-Q filed 2014-05-09.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueEquityLevel2ToLevel1TransfersAmount · last filed 2014-05-09
- 2014-03-31: Fair Value, Equity, Level 2 to Level 1 Transfers, Amount $0.00.
- 2013-12-31: Fair Value, Equity, Level 2 to Level 1 Transfers, Amount $45.50M.
- 2012-12-31: Fair Value, Equity, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Equity, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 |
| 2013-12-31 | $45.50M 10-K · filed 2014-02-20 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |